The Future of Metrology is Coming to Your Region

Join our event series.

Business Sweden: “Companies have a lot to offer in data-driven precision medicine”

Data-driven precision medicine can potentially solve major healthcare problems, states Business Sweden in a new report on the subject.

Bioscience – Groundbreaking Research & Diagnostics: Stockholm (2025)

ZEISS Quality Innovation Days: April 15 – 19, 2024

Be there when industry experts give exciting insights into different applications and trends in 90 minutes on various theme days.

From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”

A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...

Don't miss ZEISS Quality Innovation Days

Digital event April 15-19, 2024.

“We should avoid surgery if we can”

Since February this year, she has been Scientific Director Life Science at the Karolinska Institutet. Life Science Sweden met Anna Martling for a talk about rol...

ZEISS EVO as the Key to Wire Technology in Modern Medicine

High-performance wires for stents.

”The importance of stratification in a statistician’s August kitchen”

Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

Anna Törner: ”Mom, do you think you’ll ever get married again?”

”I realize I’m slowly descending into that familiar statistical rabbit hole, where life’s biggest uncertainties are reduced to point estimates and confidence in...

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

Carl Borrebaeck – professor and serial entrepreneur with a taste for speed

Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borreb...

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2025)

Many discontinue obesity medication – new study highlights the reasons

A new study maps out the most common reasons why patients choose to stop taking obesity medication prematurely. “Obesity medication discontinuation reverses hea...

Her company is developing a new tablet form obesity drug

Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...

Strategic Clarity: The New Currency in Life Science

In an industry shaped by rapid regulatory changes and global competition, leading life science companies are rethinking what it takes to succeed. Increasingly, ...

Astra Zeneca’s asthma drug nears approval for sinus inflammation

Astra Zeneca’s drug Tezspire receives positive opinion from the European Medicines Agency (EMA) for the treatment of chronic rhinosinusitis with nasal polyps.

Lundbeck presenterar första behandlingen mot MSA

Danska läkemedelsbolaget Lundbeck har utvecklat antikroppen amlenetug, som kan innebära den första behandling av multipel systematrofi (MSA).

Study: Popular diabetes treatment is not associated with thyroid cancer

Concerns raised about an association between GLP-1 analogues, used to treat diabetes and obesity, and an increased risk of thyroid cancer are not supported by a...

Controlled Pneumatics: pushing the boundaries of pneumatics

Pressure, flow rate and movement can now be controlled very precisely, and with exactly the energy actually required. Controlled Pneumatics is the combination o...

Genterapi gav hörsel till barn med medfödd dövhet – elva av tolv förbättrades

Elva av tolv barn med medfödd dövhet uppvisade förbättringar i en studie där Regenerons genterapi mot ärftlig hörselnedsättning prövades. Nu planerar det amerik...

Genmab to Acquire Dutch biotech for USD 8 Billion

Danish pharmaceutical company Genmab has agreed to acquire Dutch firm Merus, a developer of cancer therapies, for USD 8 billion, equivalent to nearly SEK 75 billion.

Mercodia AB